Holen Sie sich die Stockscreener-App
2.79
1.09%
0.03
Handel nachbörslich:
2.82
0.03
+1.08%
Schlusskurs vom Vortag:
$2.76
Offen:
$2.8
24-Stunden-Volumen:
2.70M
Relative Volume:
0.56
Marktkapitalisierung:
$454.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-175.43M
KGV:
-1.4137
EPS:
-1.9736
Netto-Cashflow:
$-143.28M
1W Leistung:
+4.10%
1M Leistung:
-10.00%
6M Leistung:
+11.16%
1J Leistung:
+92.41%
1-Tages-Spanne:
$2.74
$2.82
1-Wochen-Bereich:
$2.59
$2.825
52-Wochen-Spanne:
$1.26
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.79 | 443.51M | 0 | -175.43M | -143.28M | -1.9736 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
CABA|Cabaletta Bio Inc|Price:2.720|Chg%:+0.030 - TradingKey
BlackRock (CABA) discloses 9.6M Cabaletta Bio shares under sole control - Stock Titan
Cabaletta Bio Inc (CABA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cabaletta Bio Inc (CABA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cabaletta Bio Inc (CABA) Cash Flow - TradingKey
Cabaletta Bio Inc (CABA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cabaletta Bio Inc (CABA) Institutional Confidence - TradingKey
Cabaletta Bio Inc (CABA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cabaletta Bio Market Sentiment - Benzinga España
Cabaletta Bio Inc (CABA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cabaletta Bio Inc (CABA) Income Statement - TradingKey
Cabaletta Bio Inc (CABA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CABA|Cabaletta Bio Inc|Price:2.690|Chg%:-0.030 - TradingKey
Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cabaletta Bio, Inc. Revenue Breakdown – NASDAQ:CABA - TradingView
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio (CABA) sees Millennium group report 2.07M-share, 1.3% ownership stake - Stock Titan
Cabaletta Bio (CABA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary - Quartr
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Cabaletta Bio (CABA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
ETFs Investing in Cabaletta Bio, Inc. Stocks - TradingView
Cabaletta Bio Insider Buyers Net US$56k Despite 14% Stock Decline - 富途牛牛
Cabaletta Bio : CABA - 24/7 Wall St.
symbol__ Stock Quote Price and Forecast - CNN
Cabaletta Bio (CABA) Declines 4.49% as Stock Tests Key Support LevelsDip Buy Trade - dars.gov.et
Price to earnings forward of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
Cabaletta Bio Q1 2026 Earnings: Narrowed Loss Beats Estimates Amid Clinical ProgressFree Cash Flow Trends - dars.gov.et
Cabaletta Bio (CABA) Rallies 2.82% as Biotech Sector Sentiment ImprovesDip Buy Trade - dars.gov.et
Enterprise value to EBIT forward of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
Cabaletta Bio Inc. (CABA) Q1 2026 Earnings: Narrower-than-Feared Loss Drives Positive Investor SentimentManagement Guidance Update - dars.gov.et
Enterprise value to revenue forward of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
CABA Stock Draws Scrutiny As Ownership Filings Shift - timothysykes.com
Cabaletta Bio Inc (CABA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026. - marketscreener.com
Certain Stock Options of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026. - marketscreener.com
Certain Pre-Funded Warrants of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026. - marketscreener.com
Cabaletta Bio (CABA) Stock Forecast & Analyst Ratings - Moomoo
Cabaletta Bio Inc. Q1 2026 Earnings: EPS Beat Signals Cost Discipline Amid Pre-Revenue PhaseEPS Consistency Score - dars.gov.et
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
Cabaletta Bio, Inc.(NasdaqGS:CABA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2500 Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Value Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Value Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000 Index - marketscreener.com
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
Cabaletta Bio, Inc. Actuals & Estimates (NASDAQ:CABA) - TradingView
CABA Forecast — Price Target — Prediction for 2027 - TradingView
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cabaletta Bio Inc-Aktie (CABA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | President, Science & Tech. |
Jan 21 '26 |
Buy |
2.19 |
11,312 |
24,763 |
31,312 |
| Tomasello Shawn | Director |
Jan 21 '26 |
Buy |
2.21 |
22,725 |
50,322 |
22,725 |
| Gavel Steve | Chief Commercial Officer |
Jan 21 '26 |
Buy |
2.27 |
22,170 |
50,215 |
22,170 |
| Bollard Catherine | Director |
Jan 21 '26 |
Buy |
2.27 |
4,405 |
9,982 |
5,405 |
| Nichtberger Steven | President & CEO |
Jan 21 '26 |
Buy |
2.24 |
45,000 |
100,778 |
1,031,483 |
| Simon Mark | Director |
Jan 21 '26 |
Buy |
2.28 |
11,061 |
25,261 |
147,205 |
| Gerard Michael | General Counsel |
Jan 21 '26 |
Buy |
2.27 |
6,600 |
14,979 |
6,600 |
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):